Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Pluvicto Boosts Novartis In Radiotherapy; BMS Builds Out IO Estate With Opdualag

Mar 25 2022

• By Bridget Silverman

Keeping Track Feature image

Related Content

Foreign Data: Sintilimab’s Development Shows What Not To Do When Pursuing US Approval

Feb 16 2022

Lilly To Decide Next Steps After Formal FDA 'Nay' For First Chinese PD-1

Mar 25 2022

Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch

Mar 23 2022

BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval

Mar 21 2022

Ascendis Phase III Data Gives TransCon PTH An Edge In Hypoparathyroidism

Mar 14 2022

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Eli Lilly and Company

Innovent Biologics, Inc.

Novartis AG

Fennec Pharmaceuticals Inc.

Takeda Pharmaceutical Co. Ltd.

Additional Topics

United States Approvals Drug Approval Standards US FDA Performance Tracker BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window